ACADIA Pharma

ACADIA Pharmaceuticals, Inc. operates as a biopharmaceutical company. It focuses on the development and commercialization of medicines to address unmet medical needs in central nervous system, or CNS, disorders. The firm's products include Nuplazid, which is used for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. The company was founded by Mark R. Brann on July 16, 1993 and is headquartered in San Diego, CA.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

ACADIA Pharma reports strong Q4 earnings, eyes trofinetide launch

ACADIA Pharma showcased strong financial performance and strategic advancements in Q4 2022, with a focus on NUPLAZID and trofinetide for Rett syndrome treatment.
The company's commitment to innovation, positive payer discussions, and promising study results position it well for future success in the neuroscience space.
While facing challenges in managing expenses and post-approval logistics, ACADIA has opportunities to drive growth through market acceptance of trofinetide and expanding its patient base.
Overall, ACADIA's performance, strengths, and strategic outlook indicate a promising trajectory for the company, with key milestones ahead in 2023.

ACADIA Pharma reports solid Q1 performance and navigates strategic decisions

ACADIA Pharma's Q1 2023 performance reflects strong market acceptance of DAYBUE and steady growth in NUPLAZID market share.
The company's financial stability, progress in clinical programs, and strategic focus on real-world evidence studies position it well for future growth.
Challenges in decision-making, seasonality, and balancing profitability with pipeline expansion require strategic navigation.
Opportunities lie in exploring broader patient populations, leveraging real-world evidence, and making strategic decisions on the priority review voucher.

ACADIA Pharma reports robust Q2 sales, eyes global expansion

ACADIA Pharma's Q2 earnings call highlighted strong sales performance and milestone of cash flow neutrality
NUPLAZID and DAYBUE driving revenue growth, with plans for global expansion and new product approvals
Challenges include market dynamics in Parkinson's disease and addressing unmet needs in CNS disorders
Opportunities lie in late-stage programs, expanding market presence, and enhancing patient support initiatives

ACADIA Pharma reports robust Q3 earnings, eyes global expansion

ACADIA Pharma's Q3 2023 showcased strong financial performance, robust pipeline programs, and positive market reception for DAYBUE and NUPLAZID
Challenges with insurance coverage and study timelines were noted, but opportunities in global expansion and real-world evidence support growth potential
Overall, ACADIA Pharma's earnings call highlighted a solid foundation for continued growth and market leadership in neurological and psychiatric treatments

ACADIA Pharma posts record revenues, guides strong growth for 2024

ACADIA Pharma's Q4 earnings call highlighted strong commercial performance, robust pipeline, and solid financial position.
The company's focus on persistency rates, compliance, and guidance scenarios underpin their growth strategy for 2024.
Challenges include pipeline uncertainties and operational complexities, while opportunities lie in market expansion and optimization strategies.
Overall, ACADIA Pharma's emphasis on execution and strategic planning positions them for continued success in the pharmaceutical market.

ACADIA Pharma reports robust Q1 earnings, eyes global expansion

ACADIA Pharma's Q1 2024 showcased strong revenue growth and promising sales performance for key products.
The company's robust pipeline and focus on global expansion offer avenues for sustained growth.
Challenges in gross to net tracking and cost optimization require attention for future profitability.

ACADIA Pharma reports robust Q2 earnings, eyes market expansion opportunities

ACADIA Pharma's strong Q2 performance, driven by NUPLAZID and DAYBUE, showcases revenue growth and strategic marketing initiatives.
The company's financial stability, successful patient engagement strategies, and upcoming awareness campaigns position it well for future growth.
While facing challenges in sustaining sales momentum and market competition, ACADIA Pharma has opportunities to expand market reach and enhance therapy understanding.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

ACADIA Pharmaceuticals, Inc. engages in the development and commercialization of medicines for central nervous system disorders. Its products include Nuplazid, which is used for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. The company was founded by Mark R. Brann on July 16, 1993 and is headquartered in San Diego, CA.

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will present at the 11th Annual SVB Leerink Global Healthcare Conference on Friday, February 18, 2022, at 1:40 p.m. Eastern Time. The conference will be held virtually. A live webcast of Acadia's presentation will be accessible on the company's website, www.acadia-pharm.com, under the investors section and an archived recording will be available on the website through March 18, 2022. About Acadia Phar

Acadia Pharmaceuticals to Present at the 11th Annual SVB Leerink Global Healthcare Conference on February 18, 2022

Jazz Pharmaceuticals

Moderna

Vir Biotechnology

Let us take a look at some drug/biotech stocks like VIR, MRNA, JAZZ and ACAD that are poised to beat on fourth-quarter earnings.

4 Drug, Biotech Stocks Set to Beat Q4 Earnings Estimates

Acadia's (ACAD) Nuplazid, approved for treating hallucinations and delusions associated with Parkinson's disease psychosis, has seen strong uptake so far. Its label expansion studies also hold promise.

Acadia (ACAD) Up More Than 20% in Past 3 Months: Here's Why

Acadia (ACAD) signs a collaboration agreement with Stoke Therapeutics to develop/commercialize RNA-based medicines for addressing genetic neurodevelopmental diseases.

Acadia (ACAD) Partners With Stoke for CNS Disorder Therapies

Stoke Therapeutics Inc

SAN DIEGO & BEDFORD, Mass.--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) and Stoke Therapeutics, Inc. (Nasdaq: STOK) announced today that the companies have entered a collaboration to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the central nervous system (CNS). The collaboration includes SYNGAP1 syndrome, Rett syndrome (MECP2), and an undisclosed neurodevelopmental target of mu

Acadia Pharmaceuticals and Stoke Therapeutics Announce Collaboration to Pursue Multiple RNA-based Treatments for Severe and Rare Genetic Neurodevelopmental Diseases

The stock of Acadia Pharmaceuticals (NASDAQ: ACAD), a biopharmaceutical company focused on neuroscience drugs, has seen a rise of 26% over the last month. ACAD stock rose from levels of around $19 in early December to levels of $27 on December 20, before cooling off to levels of $24 currently.

Will Acadia Pharmaceuticals Stock See Higher Levels After A Large 26% Rally In A Month?

Albireo Pharma

Rocket Pharma

Theseus Pharmaceuticals

Xeris Biopharma Holdings

Biotech stocks remain poised to eke out modest gains for 2021 after the stellar gains of the previous year. COVID-19 drug and vaccine developers experienced volatility throughout 2021 amid delays in programs and the reemergence of variant strains.

5 Beaten Down Biotech Stocks That Could Bounce Big In 2022

The biotech saw a rebound after a down day on Tuesday.

Why Acadia Pharmaceuticals Stock Climbed More Than 10% Wednesday

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will present at the 40th Annual J.P. Morgan Healthcare Conference on Tuesday, January 11, 2022, at 10:30 a.m. Eastern Time, followed by a question and answer session. The conference will be held virtually. A live audio-only webcast of Acadia's presentation and question and answer session, along with accompanying slides, will be accessible on the company's website, www.acadia-pharm.com, under the inves

Acadia Pharmaceuticals to Present at the 40th Annual J.P. Morgan Healthcare Conference on January 11, 2022

RBC Capital raised the price target on Acadia Pharmaceuticals Inc (NASDAQ:ACAD) to $34 from $32 and kept an Outperform rating on the shares.  Analyst Gregory Renza cites the Company's confirmed intentions to resubmit the sNDA filing of pimavanserin in Alzheimer's Disease Psychosis, with a "narrower though still robust opportunity" as the largest subtype of DRP.

What Analysts Have To Say On Acadia's Narrower Nuplazid Label Expansion Bid

ACADIA (ACAD) to resubmit sNDA for Nuplazid (pimavanserin) to the FDA for treating hallucinations and delusions associated with dementia focused on Alzheimer's disease psychosis. Shares rise.

ACADIA (ACAD) Up on Resubmission Plan for Nuplazid sNDA to FDA

After suffering rejection from the FDA in April, Acadia Pharmaceuticals Inc (NASDAQ: ACAD) is making another bid to expand the scope of its Parkinson's disease med Nuplazid. Acadia plans to resubmit its application for Nuplazid (pimavanserin) to treat hallucinations and delusions associated with dementia, homing specifically on patients with Alzheimer's disease psychosis (ADP).

Acadia Slims Nuplazid Label Expansion Application For Alzheimer's Disease Psychosis

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) announced today that it plans to resubmit its supplemental New Drug Application (sNDA) for pimavanserin for the treatment of hallucinations and delusions associated with dementia focused on Alzheimer's disease psychosis (ADP). Resubmission of the sNDA to the U.S. Food and Drug Administration (FDA) is planned for the first quarter of 2022. “Following our recent meetings with the FDA, we plan to resubmit our sNDA for pimavanse

Acadia Pharmaceuticals Announces Plan for a Resubmission of its Supplemental New Drug Application to U.S. FDA for NUPLAZID® (pimavanserin)

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced the promotion of Mark Schneyer to Executive Vice President, Chief Financial Officer (CFO), effective immediately. Mr. Schneyer has served as the company's interim CFO since September 2021, while retaining his responsibilities as Acadia's head of business development and Chief Business Officer. Mr. Schneyer's responsibilities as CFO will include the functional areas of finance, accounting, investor relations,

Acadia Pharmaceuticals Announces Promotion of Mark Schneyer to Executive Vice President, Chief Financial Officer

Acadia Pharmaceuticals Inc. ( ACAD , Financial) investors finally got some good news this week when the biopharma announced positive test results for its treatment for a rare neurological condition.

Acadia Pharma Shares Jump on Positive Test Results for Rett's Drug

Acadia reported solid earnings for Q3, 2021 despite COVID-19 headwind lashing its Parkinson's Disease Psychosis [PDP] earnings. Acadia's completed Type A Meeting with the FDA has opened the door for a targeted next step.

Acadia: Big News On The Near Horizon

Cellectis SA

Intellia Therapeutics

Novavax

While markets are cautiously optimistic on the Omicron variant, these health care stocks are still hard at work.

Good Stocks To Invest In Right Now? 4 Health Care Stocks To Check Out

ACADIA's (ACAD) phase III study, evaluating the efficacy and safety of trofinetide in patients with Rett syndrome, meets co-primary endpoints. Shares rise.

ACADIA's (ACAD) Rett Syndrome Candidate Meets Goal in Study

The stock price of Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) increased by over 15% pre-market today. This is why it happened.

Acadia Pharmaceuticals Stock (ACAD): Why The Price Jumped Today

A positive clinical readout is lighting a fire underneath the biotech's shares today.

Why Acadia Pharmaceuticals Stock Is Rocketing Today

Acadia Pharmaceuticals Inc (NASDAQ: ACAD) announced topline results from Phase 3 Lavender study of trofinetide in Rett syndrome. The 12-week study demonstrated a statistically significant improvement over placebo for both co-primary endpoints.

Acadia Pharma Jumps After Rett Syndrome Candidate Aces Phase 3 Study

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced positive top-line results from the pivotal, Phase 3 Lavender™ study evaluating the efficacy and safety of trofinetide in 187 girls and young women aged 5-20 years with Rett syndrome. The 12-week placebo-controlled study demonstrated a statistically significant improvement over placebo for both co-primary endpoints. On the Rett Syndrome Behaviour Questionnaire (RSBQ), change from baseline to week 12 was -5.1 v

Acadia Pharmaceuticals Announces Positive Top-line Results from the Pivotal Phase 3 Lavender Trial of Trofinetide in Rett Syndrome

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) announced today that The Lancet Psychiatry published results from the Phase 2 ADVANCE study. ADVANCE was an international, 26-week, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of adjunctive pimavanserin treatment in outpatients with moderate-to-severe predominant negative symptoms of schizophrenia who had achieved control of positive symptoms with their ongoing antipsychotic treatmen

The Lancet Psychiatry Publishes Results from ADVANCE Study Evaluating Pimavanserin Treatment for Negative Symptoms of Schizophrenia

Acadia Healthcare's (ACHC) buyouts are helping the company to add facilities, beds and hospitals to its network and contributing to its top line.

Why Seasoned Investors are Retaining Acadia (ACHC) Stock

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced the national launch of Yours, Truly, a multicultural, storytelling campaign to bring greater awareness and understanding of the varied experiences of the non-motor symptoms associated with Parkinson's disease. In collaboration with StoryCorps, the campaign provides the Parkinson's disease community a unique forum to record, share and archive their personal stories, in both Spanish and English, while also seek

Acadia Pharmaceuticals and StoryCorps Collaborate to Launch Yours, Truly – a Multicultural Storytelling Campaign to Bring Greater Awareness to Parkinson's Disease Non-Motor Symptoms

News for ACADIA Pharma Stock (ACAD)